Evolving patterns of antimalarial drug resistance markers in symptomatic infections in Kenya, 2013–2022
Our findings reveal no WHO-validated k13 mutations up until 2022 and confirm previous findings of a reduction in the Pfcrt resistance genotypes over time. This study underscores the importance of continued molecular surveillance and suggests that resistance may evolve through different pathways in East compared with West Africa and Southeast Asia.
Authors
- Mercy Y. Akinyi (ORCID: https://orcid.org/0000-0002-3835-5793)
- Joel Ltilitan Bargul (ORCID: https://orcid.org/0000-0001-8573-6807)
- Rosebella Kiplagat
- John Magudha
- L. Isabella Ochola-Oyier
- Victor Osoti
- Kevin Wamae
- Kibor Keitany
- Hoseah M. Akala
- Regina Kandie
- Leonard Ndwiga
Institutions
- Jomo Kenyatta University of Agriculture and Technology (KE)
- United States Army Medical Research Directorate - Africa (KE)
- Kenya Medical Research Institute (KE)
- Ministry of Health (KE)
Publication Details
- Journal
- Parasites & Vectors
- Published
- 2026-02-06
- DOI
- https://doi.org/10.1186/s13071-026-07280-w
- Primary Topic
- Malaria Research and Control
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bill and Melinda Gates Foundation
- Wellcome Trust